Whereas the examine discovered that Wegovy, also called semaglutide, led to the best discount in BMI after 5 years, it was not probably the most cost-effective due its value. Essentially the most cost-effective therapy was discovered to be Qsymia, a mixture of phentermine and topiramate marketed by Vivus.
Researchers famous that the month-to-month price of Wegovy must lowered by a minimum of 85% to make it probably the most cost-effective possibility.
The examine modeled 100K teenagers with weight problems to undertaking the well being and value outcomes of way of life counseling alone or together with the weight-loss medication Qsymia, Wegovy or Saxenda, also called liraglutide.
The inputed knowledge was gathered from scientific trials, printed literature and nationwide sources, and analyzed by researchers at Columbia College Irving Medical Heart. The examine was printed on-line by the JAMA Community Open on Thursday.
All three medication are FDA permitted for the therapy of weight problems in folks aged 12 and older. Wegovy and Saxenda are each marketed by Novo Nordisk.